Definition

A fusion protein composed of two engineered human sialidase molecules fused to an Fc antibody domain, with potential immunomodulating and antineoplastic activities. Upon administration, bi-sialidase fusion protein E-602 targets and binds to sialoglycans overexpressed on the cell surface of certain tumor cells and immune cells, such as exhausted T cells. This degrades the immunosuppressive sialoglycans and allows for the re-activation of the immune system, thereby inducing an anti-tumor immune response. Sialidase is an enzymatic degrader of immunosuppressive sialoglycans. E-602 is based on the enzyme-antibody glyco-ligand editing (EAGLE) platform. The Fc domain enhances retention in the tumor, half-life and manufacturability.